These independent CME/CE activities are supported by educational grants from

Centocor Ortho Biotech Inc.

Genentech BioOncology.
The Advanced Certificate Program in
Breast Cancer Management II
  1. Curriculum III
  2. Curriculum II
  3. Curriculum I
  4. Full Course List
Chair
faculty image
Harold J. Burstein, MD, PhD
  • Associate Professor of Medicine
  • Dana-Farber Cancer Institute
  • Harvard Medical School
  • Boston, Massachusetts
    • Projects In Knowledge is pleased to present The Advanced Certificate Program: Breast Cancer Management comprised of Curricula I and II.

    Curriculum I courses present a basic overview of management strategies for optimal personalized care of breast cancer patients.
    Curriculum II presents more advanced courses that build on new scientific developments and the topics covered in Curriculum I.

    Featuring the very latest state-of-the-science information about breast cancer diagnosis, breast cancer treatment, and breast cancer disease management, this free online curriculum offers CME, CE, and CPE credit to oncologists and other clinicians who care for patients with breast cancer.

    The curriculum courses are updated continuously throughout the year.

    The Advanced Certificate Program: Breast Cancer Management is building a community of experts to help you provide your patients with the best treatment outcome possible.
  • Apply evidence-based guidelines to determine optimal treatment interventions for patients with or at risk for developing breast cancer through an understanding of the epidemiology, risk factors, and disease burden imposed by breast cancer, including genetic factors, dietary modification, morbidity, and mortality.
  • Assess the role of genetic and other markers in determining optimal treatment selection in breast cancer patients, and in evaluating treatment response to therapy to improve patient outcomes.
  • Evaluate the appropriate use of chemotherapy, hormone therapy, and targeted therapy agents in treatment strategies for breast cancer patients that improve outcomes through knowledge of their efficacy and safety.
  • Assess the challenges in promoting treatment compliance, including long-term compliance, and address the long-term consequences of treatment.
    • Early-stage breast cancer management
      • Chemotherapy
      • Endocrine/hormone therapy
      • Targeted therapy
      • Bisphosphonates
    • Metastatic breast cancer management
      • Chemotherapy
      • Hormone therapy
      • Targeted therapies
        - Anti-HER2 agents
        - Antiangiogenic agents
        - PARP inhibitors
      • Bone metastasis management
    • Neoadjuvant therapy
      • Translational therapy
    • Hereditary breast cancer
    • Adjuvant treatment for premenopausal and postmenopausal women
    • Hormone-receptor-positive breast cancer
    • Primary endocrine therapy
    • Estrogen-receptor-positive breast cancer
    • Third-line chemotherapy in metastatic breast cancer
    • Biomolecular predictors
    • Adjuvant systemic therapy in early-stage breast cancer
    • Estrogen-responsive genes in metastases to the bone
    • Cancer risk assessment with biomarkers
    • Postoperative treatment with targeted therapies for patients with HER2+ & HER2-
    • Dose-dense adjuvant therapy
    • Hormonal therapy for advanced breast cancer
    • Neoadjuvant systemic therapy
    • Molecular screening for breast cancer
    • 21-gene recurrence score prognostic assay
    • Small (subcentimeter) HER2+ breast cancer
    • Triple-negative breast cancer
    • Endocrine-sensitive, HER2- breast cancer in postmenopausal women

    Target Audience

    This series of activities is designed for medical oncologists and other clinicians involved in the care of patients with breast cancer.

     

    Activity Goal

    The goal of these CME/CE activities is to examine current and emerging strategies for diagnosing, treating, and managing patients with breast cancer.